Production Technician
About the job
- The role requires introductory work experience in the field.
- A bachelor's degree from a recognized higher-education institution, or a high-school education combined with corresponding work experience, is required.
- Have strong oral and written communication, interpersonal, leadership, independent-work, and problem-solving abilities.
- Work well as part of a team.
- Attend regular training, become familiar with current cGMP and EHS requirements, develop production-related professional skills and knowledge, and continue improving.
- Carry out production according to appropriate instructions.
- Use business judgment developed through education or past experience and understand how the team's work contributes to the area.
- Solve problems using established procedures and consult a supervisor or senior team member when an issue falls outside defined instructions or parameters.
- Collaborate with others to solve problems; in customer-facing work, build customer relationships, serve as the interface between the customer and GE HealthCare, communicate technical information, ask questions, and confirm understanding.
- Accept work assignments from a supervisor or team leader.
- Train and guide other employees in equipment operation.
- Follow cGMP, standard operating procedures, and EHS requirements during production; complete batch documents and logbooks accurately and on time.
- Perform machine changeovers and routine condition checks.
- Carry out in-process controls during production according to batch documentation.
- Monitor overall equipment effectiveness data collection and participate in production-data analysis.
- Fulfill responsibilities set out in the current GE HealthCare EHS policy and meet the Shanghai factory's EHS expectations.
- Promptly report deviations and abnormal machine or operating conditions and actively seek solutions.
- Participate in technical-improvement projects and work closely with Engineering, Validation, and Project departments to complete periodic equipment validation or special validation projects.
- Support Engineering with routine equipment maintenance and production-equipment repair and servicing.
About the company
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
- CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
- CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.
What critics are saying
- FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
- Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
- SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.
What makes GE Healthcare unique
- GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
- Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
- SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.
AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.
GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.
GE HealthCare has launched CareIntellect for Operations, an AI-powered software application that helps health systems forecast capacity constraints up to 72 hours ahead. The solution analyses hundreds of patient and operational data points to predict bottlenecks and recommend actions to optimise capacity and throughput. The Queen's Health Systems and Duke Health will be the first to implement the application. It uses two proprietary AI models: the Pressure Forecast model, which predicts resource constraints across hospitals and departments, and the Estimated Day of Discharge model, which predicts when patients will be discharged. The tool addresses operational challenges as US inpatient volumes rose 5.3% in 2025, requiring health systems to manage increased demand whilst facing staffing shortages and rising costs.
GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.